Compare Stocks: UTHR, ARGX, MRNA, and NTRA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$1,007.71 -2.5%	$928.88	$661.85 ▼ $1,072.75	$63.10B	0.47	340,074 shs	30,640 shs
MRNA Moderna	$143.44 -1.5%	$87.26	$22.28 ▼ $176.66	$57.14B	1.1	11.59 million shs	2.31 million shs
NTRA Natera	$323.92 -1.3%	$293.74	$157.43 ▼ $343.18	$46.64B	1.54	1.34 million shs	94,832 shs
UTHR United Therapeutics	$495.98 +1.7%	$524.81	$392.17 ▼ $609.35	$21.26B	0.56	490,601 shs	102,149 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	0.00%	+0.14%	+19.43%	+16.87%	+37.61%
MRNA Moderna	0.00%	+3.71%	+145.99%	+204.94%	+478.96%
NTRA Natera	0.00%	+1.93%	+1.89%	+47.28%	+95.32%
UTHR United Therapeutics	0.00%	-4.46%	-9.51%	-11.85%	+21.74%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$1,007.71 -2.5%	$928.88	$661.85 ▼ $1,072.75	$63.10B	0.47	340,074 shs	30,640 shs
MRNA Moderna	$143.44 -1.5%	$87.26	$22.28 ▼ $176.66	$57.14B	1.1	11.59 million shs	2.31 million shs
NTRA Natera	$323.92 -1.3%	$293.74	$157.43 ▼ $343.18	$46.64B	1.54	1.34 million shs	94,832 shs
UTHR United Therapeutics	$495.98 +1.7%	$524.81	$392.17 ▼ $609.35	$21.26B	0.56	490,601 shs	102,149 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	0.00%	+0.14%	+19.43%	+16.87%	+37.61%
MRNA Moderna	0.00%	+3.71%	+145.99%	+204.94%	+478.96%
NTRA Natera	0.00%	+1.93%	+1.89%	+47.28%	+95.32%
UTHR United Therapeutics	0.00%	-4.46%	-9.51%	-11.85%	+21.74%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARGX argenex	2.88	Moderate Buy	$1,158.61	14.97% Upside
MRNA Moderna	2.08	Hold	$76.72	-46.51% Downside
NTRA Natera	2.83	Moderate Buy	$322.50	-0.44% Downside
UTHR United Therapeutics	2.85	Moderate Buy	$646.00	30.25% Upside

Current Analyst Ratings Breakdown

Latest UTHR, ARGX, MRNA, and NTRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/8/2026	NTRA Natera	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$385.00
9/8/2026	NTRA Natera	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Outperform ➝ Buy
9/3/2026	MRNA Moderna	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$81.00
9/3/2026	MRNA Moderna	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Sell
9/3/2026	ARGX argenex	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$1,150.00
9/3/2026	MRNA Moderna	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Neutral ➝ Sell	$40.00 ➝ $81.00
8/31/2026	ARGX argenex	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$1,230.00 ➝ $1,250.00
8/28/2026	MRNA Moderna	CLSA Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Outperform
8/28/2026	MRNA Moderna	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold
8/28/2026	MRNA Moderna	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
8/28/2026	MRNA Moderna	Bradesco Corretora Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Outperform

(Data available from 9/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARGX argenex	$4.25B	14.84	$20.81 per share	48.43	$118.34 per share	8.52
MRNA Moderna	$1.94B	29.46	N/A	N/A	$22.14 per share	6.48
NTRA Natera	$2.31B	20.25	N/A	N/A	$12.38 per share	26.16
UTHR United Therapeutics	$3.18B	6.68	$33.56 per share	14.78	$164.81 per share	3.01

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARGX argenex	$1.29B	$26.04	38.73	27.04	1.07	32.19%	43.59%	36.66%	N/A
MRNA Moderna	-$2.82B	-$7.99	N/A	N/A	N/A	-141.43%	-28.30%	-19.39%	11/5/2026 (Estimated)
NTRA Natera	-$208.16M	-$1.36	N/A	32,391.70	N/A	-7.11%	-11.38%	-7.87%	11/5/2026 (Estimated)
UTHR United Therapeutics	$1.33B	$27.95	17.74	16.72	2.43	41.56%	20.18%	17.98%	11/4/2026 (Estimated)

Latest UTHR, ARGX, MRNA, and NTRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	NTRA Natera	-$0.4939	-$0.47	+$0.0239	-$0.47	$661.24 million	$752.75 million
8/5/2026	Q2 2026	UTHR United Therapeutics	$6.86	$7.27	+$0.41	$7.27	$804.65 million	$783.30 million
7/31/2026	Q2 2026	MRNA Moderna	-$2.03	-$1.97	+$0.06	-$1.97	$102.93 million	$145.00 million
7/21/2026	Q2 2026	ARGX argenex	$5.86	$7.32	+$1.46	$7.32	$1.45 billion	$1.54 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARGX argenex	N/A	N/A	N/A	N/A	N/A
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
NTRA Natera	N/A	N/A	N/A	N/A	N/A
UTHR United Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARGX argenex	N/A	5.12	4.89
MRNA Moderna	0.09	2.29	2.18
NTRA Natera	N/A	3.00	2.85
UTHR United Therapeutics	N/A	5.73	5.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARGX argenex	60.32%
MRNA Moderna	75.33%
NTRA Natera	99.90%
UTHR United Therapeutics	94.08%

Insider Ownership

Company	Insider Ownership
ARGX argenex	2.43%
MRNA Moderna	10.80%
NTRA Natera	5.05%
UTHR United Therapeutics	8.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARGX argenex	1,863	62.56 million	61.04 million	Optionable
MRNA Moderna	4,700	399.24 million	356.12 million	Optionable
NTRA Natera	6,140	144.14 million	136.87 million	Optionable
UTHR United Therapeutics	1,400	42.89 million	39.20 million	Optionable

UTHR, ARGX, MRNA, and NTRA Headlines

Recent News About These Companies

United Therapeutics Corporation Announces Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion Authorization

2 hours ago | markets.ft.com

California State Teachers Retirement System Grows Stake in United Therapeutics Corporation $UTHR

September 8 at 4:24 AM | marketbeat.com

Hsbc Holdings PLC Raises Stake in United Therapeutics Corporation $UTHR

September 8 at 3:52 AM | marketbeat.com

16,970 Shares in United Therapeutics Corporation $UTHR Purchased by Nykredit A S

September 6 at 5:03 AM | marketbeat.com

United Therapeutics (NASDAQ:UTHR) CEO Sells $4,687,870.00 in Stock

September 6 at 4:07 AM | americanbankingnews.com

Insider Selling: United Therapeutics (NASDAQ:UTHR) EVP Sells $4,000,849.00 in Stock

September 6 at 4:07 AM | americanbankingnews.com

Odyssean LLC Purchases 2,358 Shares of United Therapeutics Corporation $UTHR

September 5 at 4:55 AM | marketbeat.com

United Therapeutics (UTHR) Down 8% Since Last Earnings Report: Can It Rebound?

September 4, 2026 | zacks.com

United Therapeutics (NASDAQ:UTHR) EVP Sells 8,300 Shares

September 4, 2026 | insidertrades.com

United Therapeutics (NASDAQ:UTHR) Stock Price Down 4.7% on Insider Selling

September 4, 2026 | americanbankingnews.com

Insider Selling: United Therapeutics (NASDAQ:UTHR) EVP Sells 8,300 Shares of Stock

September 3, 2026 | marketbeat.com

United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Stock

September 3, 2026 | marketbeat.com

FDA Accepts UTHR's sNDA for Tyvaso in Idiopathic Pulmonary Fibrosis

September 3, 2026 | zacks.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: United Therapeutics (UTHR) and Medtronic (MDT)

September 3, 2026 | theglobeandmail.com

FDA Accepts UTHR's sNDA for Tyvaso in Idiopathic Pulmonary Fibrosis

September 3, 2026 | finance.yahoo.com

United Therapeutics Corporation Announces FDA Acceptance of Supplemental New Drug Application for Nebulized Tyvaso® to Treat Idiopathic Pulmonary Fibrosis

September 2, 2026 | rutlandherald.comR

United Therapeutics Announces FDA Acceptance Of SNDA For Nebulized Tyvaso In IPF

September 2, 2026 | rttnews.com

United Therapeutics bid to expand nebulized Tyvaso label gets FDA review

September 2, 2026 | msn.com

United Therapeutics Slides as Investors Weigh Insider Selling Against a New Regulatory Milestone

September 2, 2026 | quiverquant.comQ

United Therapeutics (NASDAQ:UTHR) Shares Down 4.7% on Insider Selling

September 2, 2026 | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $118.21 Million Position in United Therapeutics Corporation $UTHR

September 2, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

UTHR, ARGX, MRNA, and NTRA Company Descriptions

argenex NASDAQ:ARGX

$1,007.71 -25.44 (-2.46%)

As of 10:19 AM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Moderna NASDAQ:MRNA

$143.44 -2.11 (-1.45%)

As of 10:20 AM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Natera NASDAQ:NTRA

$323.92 -4.26 (-1.30%)

As of 10:20 AM Eastern

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

United Therapeutics NASDAQ:UTHR

$495.98 +8.37 (+1.72%)

As of 10:20 AM Eastern

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest UTHR, ARGX, MRNA, and NTRA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest UTHR, ARGX, MRNA, and NTRA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

UTHR, ARGX, MRNA, and NTRA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

UTHR, ARGX, MRNA, and NTRA Company Descriptions

argenex NASDAQ:ARGX

Moderna NASDAQ:MRNA

Natera NASDAQ:NTRA

United Therapeutics NASDAQ:UTHR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest UTHR, ARGX, MRNA, and NTRA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest UTHR, ARGX, MRNA, and NTRA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

UTHR, ARGX, MRNA, and NTRA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

UTHR, ARGX, MRNA, and NTRA Company Descriptions

argenex NASDAQ:ARGX

Moderna NASDAQ:MRNA

Natera NASDAQ:NTRA

United Therapeutics NASDAQ:UTHR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools